Stockreport

Molecular Templates Announces Dosing of First Patient in Phase 1 Expansion Study of MT-3724 in Diffuse Large B-Cell Lymphoma (DLBCL)

Molecular Templates, Inc.  (MTEM) 
Last molecular templates, inc. earnings: 11/12 05:00 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.mtem.com/investor-relations
PDF - Maximum Tolerated Dose of MT-3724 Identified AUSTIN, Texas, Oct. 24, 2017 (GLOBE NEWSWIRE) -- Molecular Templates, Inc., (Nasdaq:MTEM) a clinical stage biopharmaceu [Read more]